Omid Zamani

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Richard Furie, Michelle Petri, Omid Zamani et al. · Arthritis & Rheumatism · 2011 · 1.7K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Dae‐Hyun Yoo, Paweł Hrycaj, Pedro C. Miranda et al. · Annals of the Rheumatic Diseases · 2013 · 653 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Baricitinib in Patients with Refractory Rheumatoid Arthritis

Mark C. Genovese, Joel Kremer, Omid Zamani et al. · New England Journal of Medicine · 2016 · 621 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study

M. C. Genovese, Joel M. Kremer, Omid Zamani et al. · Annals of the Rheumatic Diseases · 2015 · 27 citations

Medicine, Pharmacology, Pharmacotherapy +14

Comparison of safety, efficacy and tolerability of Dexibuprofen and Ibuprofen in the treatment of osteoarthritis of the hip or knee

Omid Zamani, Elke Böttcher, Jörg D. Rieger et al. · Wiener klinische Wochenschrift · 2014 · 12 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +6